Electrochemotherapy with a trans platinum compound

What is it about?

In vitro and in vivo evaluation of electrochemotherapy with trans platinum compound, containing hydroximethil ligand (trans-[PtCl2(3-Hmpy)2] (3-Hmpy = 3-hydroxymethylpyridine) (compound 2)). To improve compound 2 cytotoxicity in vitro and antitumor efficiency in vivo, electroporation was used as drug delivery approach in order to increase membrane permeability (electrochemotherapy). We have shown electroporation increased cytotoxicity in vitro and tumor response to compound 2 in vivo. Thus, obtained results suggest compound 2 as a possible antitumor agent in electrochemotherapy.

Featured Image

Why is it important?

Our findings show that cisplatin trans analogue, compound 2, could be potentially used in preclinical studies of electrochemotherapy.

Perspectives